Targeted B7H3 Program (Full Life Technologies)

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameTargeted B7H3 Program (Full Life Technologies)
Drug Alias NameN/A
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225Ac
Mechanisms of ActionIonising radiation emittersCD276 antigen inhibitors
TargetsCD276 antigen
Therapy Area/IndicationsSmall Cell Lung CarcinomaColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFull Life Technologies Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFull Life Technologies Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A